Antibody formation and its impact on long-term graft outcome.
Rose
M L
ML
National Heart and Lung Institute, Imperial College School of Medicine, Harefield Hospital, Harefield, Middlesex, UK.
Smith
J D
JD
Lawson
C
C
D000917:Antibody Formation; D002478:Cells, Cultured; D004730:Endothelium, Vascular / Q000187:drug effects / Q000276:immunology / Q000502:physiology*; D006085:Graft Survival / Q000276:immunology / Q000502:physiology*; D015788:HLA-A1 Antigen / Q000276:immunology*; D015789:HLA-A2 Antigen / Q000276:immunology*; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology* / Q000494:pharmacology; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007518:Isoantibodies / Q000276:immunology / Q000494:pharmacology; D016328:NF-kappa B / Q000378:metabolism; D013601:T-Lymphocytes / Q000276:immunology; D013997:Time Factors; D014181:Transplantation Immunology; D016896:Treatment Outcome; D014471:Umbilical Veins
D015788:HLA-A1 Antigen; D015789:HLA-A2 Antigen; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D007518:Isoantibodies; D016328:NF-kappa B